

Foveal thinning in neuromyelitis optica

A sign of retinal astrocytopathy?

OPEN

Takashi Yamamura, MD,
PhD
Ichiro Nakashima, MD,
PhD

Correspondence to
Dr. Yamamura:
yamamura@ncnp.go.jp

*Neurol Neuroimmunol
Neuroinflamm*
2017;4:e347; doi: 10.1212/
NXL.0000000000000347

Patients with neuromyelitis optica spectrum disorder (NMOSD) typically manifest recurrent episodes of optic neuritis (ON) and myelitis. Recently revised diagnostic criteria¹ do not restrict the diagnosis of NMOSD to patients associated with elevation of anti-aquaporin 4 antibody (AQP4Ab), capable of causing destruction of astrocytes expressing AQP4. If compatible clinical and radiologic features are present, the diagnosis of NMOSD is given to patients with autoantibodies (Ab) specific for myelin oligodendrocyte glycoprotein (MOG).² However, compared with MOGAb+ NMOSD, clinical relapses tend to be more serious in AQP4Ab+ patients and could result in devastating neurologic sequelae manifested by blindness, paralysis, cognitive dysfunction, or neurogenic pain.

While acute relapses are characteristic of the relapsing-remitting form of MS, insidious worsening related to chronic neuroinflammation is the basis for the diagnosis of secondary progressive MS. Although secondary progressive disease was assumed to be uncommon in NMOSD,³ recent studies relying on MRI findings have described progressive brain or spinal cord atrophy^{4,5} without a sign of relapses in patients with AQP4Ab+ NMOSD.

In this issue of *Neurology*[®] *Neuroimmunology & Neuroinflammation*, Oertel et al.⁶ measured the foveal thickness and the thickness of surrounding structures (peripapillary retinal nerve fiber layer and ganglion cell and inner plexiform layers) in patients with NMOSD using optical coherence tomography (OCT). They compared eyes from patients who had long extensive spinal cord lesions archetypal for NMOSD but no history of ON with eyes from NMOSD patients with history of ON and eyes from healthy controls. In parallel, diffusion tensor imaging (DTI) was used to evaluate the microstructural changes in the optic radiation, which is responsible for transmitting visual signals from the retina to the visual cortex. The authors demonstrate that central foveal thickness is significantly reduced in the eyes of

the 6 patients without a history of ON as compared to controls, although high-contrast visual acuity of these patients was normal. Fovea is a tiny pit in the macula of the retina and is responsible for the central, high-resolution color vision. As the fovea is enriched in Müller cells expressing AQP4, their observation suggests the occurrence of primary retinal astrocytopathy in NMOSD. DTI analysis also showed secondary microstructural changes in the afferent visual system in parallel with the foveal thinning. Shortly before this publication,⁶ OCT was applied by Korean and Japanese groups for the analysis of retinal changes in patients with NMOSD.^{7,8} Notably, the Korean study also showed the presence of foveal thinning in the retina of unaffected eyes of patients with NMOSD. Moreover, the foveal thinning was correlated with a reduction in low-contrast visual acuity in the Korean study, implying that the retina of the “unaffected eyes” in AQP4Ab+ NMOSD might be actually damaged by chronic autoimmune inflammation targeting Müller cells or retinal astrocytes.

One could say that prevention of relapses is a goal of therapy for NMOSD, assuming that only serious relapses are thought to cause neurologic sequelae. However, the presence of retinal changes without previous ON indicates that an insidious development of pathology cannot be ignored in patients with NMOSD. Given that the life expectancy of patients with NMOSD has substantially improved, the future goal of therapy should not only be prevention of relapses, but prevention of new lesion development by immunotherapy under close monitoring. Alterations in Müller cells have been also described in a rodent model of NMOSD.⁹ This pathology was dependent on both AQP4Ab and T cells, indicating the importance of T-cell control to achieve good control of NMOSD.

It is known that the shape and size of retinal fovea evaluated by OCT differ among different ethnic

See article

From the National Institute of Neuroscience (T.Y.), NCNP, Kodaira, Tokyo; and Department of Neurology (I.N.), Tohoku University School of Medicine, Aoba-ku, Sendai, Japan.

Funding information and disclosures are provided at the end of the editorial. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was funded by *Neurology: Neuroimmunology & Neuroinflammation*.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

groups. In this regard, data from both Caucasian and Asian patients are precious and useful. The size of the avascular area in the fovea may influence OCT evaluation.¹⁰ Therefore, future studies should evaluate the avascular area as well.

The study by Oertel et al.⁶ together with recent publications from other investigators^{7,8} have begun to stimulate discussion about the goal of therapy in patients with NMOSD regarding the prognosis of visual function. However, it is too early to make any conclusion until the reproducibility of the results is confirmed in prospective studies involving more patients.

STUDY FUNDING

No targeted funding reported.

DISCLOSURE

T. Yamamura served on the scientific advisory board for Biogen Japan, Chugai Pharmaceutical Co, and Takeda Pharmaceutical Company; received travel funding and/or speaker honoraria from Novartis, Nihon, Santen, Abbott Japan/Eisai, Biogen Japan, Dainippon Sumitomo, Bayer Holding, and Astellas Pharma Inc Takeda; and received research support from Ono, Chugai, Teva, Mitsubishi Tanabe Pharma, Asahi Kuraray Medical, and Ministry of Health, Labour, and Welfare of Japan. I. Nakashima received travel funding and speaker honoraria from Mitsubishi Tanabe Pharma and Novartis; is an editorial board member for *Multiple Sclerosis International*; and received grant support from LKI Medicine Corporation. Go to Neurology.org/nn for full disclosure forms.

REFERENCES

1. Wingerchuk D, Banwell B, Bennett J, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology* 2015;85:177–189.

2. Ikeda K, Kiyota N, Kuroda H, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. *Mult Scler* 2015;21:656–659.
3. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. *Neurology* 2007;68:603–605.
4. Warabi Y, Takahashi T, Isozaki E. Progressive cerebral atrophy in neuromyelitis optica. *Mult Scler* 2015;21:1872–1875.
5. Ventura RE, Kister I, Chung S, et al. Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. *Neurol Neuroimmunol Neuroinflamm* 2016;3:e224. doi: 10.1212/NXI.0000000000000224.
6. Oertel F, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. *Neurol Neuroimmunol Neuroinflamm* 2017;4:e334. doi: 10.1212/NXI.0000000000000334.
7. Jeong IH, Kim HJ, Kim NH, Jeong KS, Park CY. Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder. *J Neurol* 2016;263:1343–1348.
8. Matsumoto Y, Mori S, Ueda K, et al. Impact of the anti-aquaporin-4 autoantibody on inner retinal structure, function and structure-function associations in Japanese patients with optic neuritis. *PLoS One* 2017;12:e0171880.
9. Zeka B, Hastermann M, Kaufmann N, et al. Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD. *Acta Neuropathol Commun* 2016;4:82.
10. Tick S, Rossant F, Ghorbel I, et al. Foveal shape and structure in a normal population. *Invest Ophthalmol Vis Sci* 2011;52:5105–5110.

Neurology[®] Neuroimmunology & Neuroinflammation

Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy?

Takashi Yamamura and Ichiro Nakashima
Neurol Neuroimmunol Neuroinflamm 2017;4;
DOI 10.1212/NXI.0000000000000347

This information is current as of April 11, 2017

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/4/3/e347.full.html
References	This article cites 10 articles, 1 of which you can access for free at: http://nn.neurology.org/content/4/3/e347.full.html##ref-list-1
Citations	This article has been cited by 2 HighWire-hosted articles: http://nn.neurology.org/content/4/3/e347.full.html##otherarticles
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.

